Oculis (NASDAQ:OCS) Shares Gap Up – Time to Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) gapped up prior to trading on Wednesday . The stock had previously closed at $15.37, but opened at $15.89. Oculis shares last traded at $15.89, with a volume of 316 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $29.20.

Oculis Price Performance

The company’s 50 day simple moving average is $15.09 and its 200-day simple moving average is $12.95. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $643.55 million, a price-to-earnings ratio of -7.96 and a beta of -0.34.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.